Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 14/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848928 | 0.90 | P2RY12 (0.59) | P2RY12MEN1KMT2A | |
| SCHEMBL5849213 | 0.89 | P2RY12 (0.51) | P2RY12MEN1KMT2A | |
| SCHEMBL5849494 | 0.89 | P2RY12 (0.49) | P2RY12MEN1KMT2A | |
| SCHEMBL5850838 | 0.89 | P2RY12 (0.53) | P2RY12MEN1KMT2A | |
| SCHEMBL5850723 | 0.87 | P2RY12 (0.50) | P2RY12MEN1KMT2A | |
| SCHEMBL5851220 | 0.87 | P2RY12 (0.44) | P2RY12MEN1KMT2A | |
| SCHEMBL5849059 | 0.87 | P2RY12 (0.44) | P2RY12MEN1KMT2A | |
| SCHEMBL5849680 | 0.87 | P2RY12 (0.46) | P2RY12MEN1KMT2A | |
| SCHEMBL5850752 | 0.86 | P2RY12 (0.44) | P2RY12MEN1KMT2A | |
| SCHEMBL5851312 | 0.85 | KDM4E (0.56) | P2RY12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | P2RY12 111/4885MEN1 2603/4885KMT2A 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.